Study of SNX-5422 in TP53 Null Cancers

Exclusion Criteria

• •Treatment with an investigational agent within 30 days prior to the first dose of SNX-5422 or planning to receive an investigational agent during the study.
• •Treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer therapy (whichever is shorter) is prohibited from 30 days prior to the first dose of SNX-5422 and throughout the study.
• •Radiation treatment within 2 weeks.
• •The need for treatment with medications with clinically relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422 (Appendix B).
• •Appropriately corrected screening ECG QTc interval 470 msec for females, 450 msec for males.
• •Currently receiving medications known to cause QT prolongation AND corrected QTc of 450 msec for females, 430 msec for males.
• •Patients with chronic diarrhea of grade 2 or greater despite maximal medical management.
• •Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
• •Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
• •History of documented adrenal dysfunction not due to malignancy.
• •Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
• •History of chronic liver disease.
• •Active hepatitis A or B.
• •Current alcohol dependence or drug abuse.
• •Clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.
• •Other serious concurrent illness or medical condition.